What is IDEXX Laboratories?
Veterinary diagnostics and software company with $4.304B 2025 revenue scale and public-market buying capacity.
- Category
- Veterinary diagnostics and software
- Headquarters
- Westbrook, ME
- Founded
- 1983
- Employees
- 11,000+
- Total funding
- Public company; no VC funding
- Status
- Nasdaq: IDXX; Public company
What is IDEXX Laboratories?
IDEXX Laboratories is a public veterinary diagnostics and software company headquartered in Westbrook, ME. IDEXX 2025 revenue reached approximately $4.304 billion, and the company raised 2026 guidance after reporting Q1 2026 revenue of $1.141 billion.
IDEXX Laboratories operates in veterinary diagnostics and software with a portfolio that includes Catalyst analyzers, SNAP tests, Reference laboratories, VetConnect PLUS. IDEXX 2025 revenue reached approximately $4.304 billion, and the company raised 2026 guidance after reporting Q1 2026 revenue of $1.141 billion. The company employs about 11,000+ and trades as Nasdaq: IDXX, so its buying motion looks like a regulated enterprise account rather than a startup account.
Its scale comes from clinically regulated products, payer or provider relationships, recurring consumables or services, intellectual property, manufacturing quality systems, and commercial access. Customers and partners evaluate IDEXX Laboratories through clinical outcomes, regulatory execution, supply reliability, reimbursement, data security, and total cost of care.
For sellers, IDEXX Laboratories is a multi-stakeholder account. Procurement, finance, clinical, quality, regulatory, legal, privacy, security, IT, operations, commercial, and business-unit leaders can all influence vendor approval. Strong pitches connect directly to patient impact, compliance, revenue capture, operating leverage, risk reduction, uptime, or measurable productivity.
What does IDEXX Laboratories offer?
IDEXX Laboratories offers products and services across Catalyst analyzers, SNAP tests, Reference laboratories, VetConnect PLUS and related healthcare workflows.
- Catalyst analyzers· In-clinic diagnostics
- SNAP tests· Point-of-care diagnostics
- Reference laboratories· Lab services
- VetConnect PLUS· Software
- IDEXX Cornerstone· Practice management
- Water microbiology testing· Water diagnostics
How does IDEXX Laboratories make money?
IDEXX Laboratories earns revenue through regulated healthcare products, services, recurring consumables, software-enabled workflows, market access, and enterprise contracts.
IDEXX Laboratories earns revenue from products and services sold to healthcare systems, clinicians, payers, labs, pharmacies, governments, distributors, life-science customers, or patients depending on the business line. In 2025, that model produced $4.304B 2025 of reported revenue scale. Growth is tied to product demand, procedure or test volumes, prescription access, installed-base utilization, new indications, geographic reach, and disciplined pricing.
Pricing is not a public self-serve tier. It is negotiated by therapy, device, test, payer coverage, account type, contract term, service level, GPO or distributor structure, reimbursement, and geography. The practical tiers are enterprise account segmentation, clinical evidence review, value-analysis committee approval, data/security review, legal terms, and renewal or tender economics.
Vendors should expect mature procurement and high evidence requirements. Budgets open when a proposal helps IDEXX Laboratories improve launch execution, manufacturing resilience, clinical operations, data quality, regulatory readiness, patient access, field productivity, cybersecurity, or cost-to-serve.
Who leads IDEXX Laboratories?
IDEXX Laboratories is led by Jay Mazelsky, with finance, R&D, commercial, technology, medical, operations, and business-unit leaders shaping major enterprise decisions.
- Jay MazelskyPresident and Chief Executive OfficerCEO since 2019Leads companion-animal diagnostics, software, and recurring-revenue growth.
- Brian McKeonExecutive Vice President and Chief Financial OfficerCFO since 2003Oversees finance and capital allocation.
- Michael LaneExecutive Vice President and General Manager, Reference Laboratories and TelemedicineSenior business leaderRuns key laboratory and telemedicine operations.
- Michael SchreckExecutive Vice President and Chief Commercial OfficerCommercial leaderLeads global commercial execution.
How do you contact IDEXX Laboratories's leadership?
IDEXX Laboratories publishes official IDEXX investor-relations contact route, but it does not publish verified personal executive emails for the leaders listed here. Use the official investor, media, supplier, compliance, or contact form routes rather than guessed personal addresses.
official IDEXX investor-relations contact route; personal executive email format not verified- Brian McKeonExecutive Vice President and Chief Financial Officerofficial IDEXX investor-relations contact route
- Michael LaneExecutive Vice President and General Manager, Reference Laboratories and Telemedicineofficial IDEXX investor-relations contact route
How much funding has IDEXX Laboratories raised?
IDEXX Laboratories is a mature public company, not a venture-backed startup. It trades as Nasdaq: IDXX and funds growth through operating cash flow, public-market access, debt markets, partnerships, and acquisition capacity.
IDEXX Laboratories's capital history is a public-company story rather than a disclosed venture-round history. The relevant funding events are founding, public listing, major acquisitions or divestitures, retained earnings, debt capacity, R&D reinvestment, manufacturing investment, and shareholder capital allocation.
As of June 2026, the current capital lens is Nasdaq: IDXX, $4.304B 2025 of 2025 revenue scale, and management's ability to fund launches, facilities, technology, clinical programs, supply chain, compliance, and business development. That is materially different from a startup where the next round controls hiring and tool budgets.
Seller signal: IDEXX Laboratories has enterprise buying power, but budget access is tied to risk, ROI, auditability, executive sponsorship, and integration fit. Procurement is more likely to approve projects that reduce operational friction, protect regulated workflows, improve patient or customer outcomes, or support a named business priority.
How did IDEXX Laboratories get here?
IDEXX Laboratories grew through founding, product expansion, public-market scale, strategic portfolio moves, and regulated healthcare execution.
- 1983IDEXX foundedThe company starts in Maine focused on diagnostics.
- 1991IPOIDEXX becomes public.
- 2000sIn-clinic diagnostics scaleAnalyzer and SNAP test adoption deepens veterinary customer relationships.
- 2019Jay Mazelsky becomes CEOIDEXX transitions to current leadership.
- 2025$4.304B revenueIDEXX reaches approximately $4.304 billion in 2025 revenue.
- 2026Guidance raisedIDEXX raises 2026 revenue guidance after Q1 outperformance.
Who are IDEXX Laboratories's competitors?
IDEXX Laboratories competes with large healthcare, pharma, diagnostics, life-science, and medtech companies that overlap in products, customers, procurement budgets, and clinical workflows.
- ZoetisCompetes in animal health diagnostics, therapeutics, and veterinary relationships.
- Antech DiagnosticsCompetes in veterinary reference labs and diagnostic services.
- CovetrusCompetes in veterinary software, distribution, and practice workflows.
- Thermo Fisher ScientificCompetes in diagnostics instruments, reagents, and laboratory workflows.
- Mars Veterinary HealthCompetes indirectly through veterinary networks and diagnostic demand.
- VirbacCompetes in animal health products and veterinary customer relationships.
IDEXX Laboratories — frequently asked questions
